Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad35.CS.01/Ad26.CS.01 prime-boost vaccine for malaria
NCT01397227Phase 2Completed
- Sponsor
- Crucell
- Start
- Jun 2011
- Primary completion
- May 2012
- Modality
- Gene Editing, Viral Vector Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of Ad35.CS.01, Ad26.CS.01 in malaria, sponsored by Crucell. Started Jun 2011; status: completed.
02
Drugs
Ad35.CS.01Ad26.CS.01
03
Conditions
malaria
Beyond the preview
Go deeper on NCT01397227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01397227.